Position in MRK
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$320,350
-$1,761,869 QoQ
Shares Held
2,493
-90.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#3,112
of 3,769 holders
Holding Since
Mar 2022
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026GSA CAPITAL PARTNERS LLP holds $7,172,969 across 8 Drug Manufacturers - General names. MRK ranks #8 (4.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BMY |
Bristol Myers Squibb Co
|
28,898 | $1,665,102 | |
| 2 | LLY |
ELI LILLY & Co
|
1,075 | $1,289,387 | |
| 3 | GILD |
Gilead Sciences, Inc.
|
9,877 | $1,247,860 | |
| 4 | AMGN |
Amgen Inc
|
2,641 | $956,358 | |
| 5 | GRFS |
Grifols SA
|
101,833 | $720,977 | |
| 6 | SNY |
Sanofi
|
12,660 | $540,075 | |
| 7 | NVS |
Novartis AG
|
2,762 | $432,860 | |
| 8 | MRK |
Merck & Co., Inc.
This page
|
2,493 | $320,350 |
All Filings in MRK
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $320,350 | 2,493 | Shares | Sole | 2026-08-06 | |
| 2025-09-30 | $2,082,219 | 24,809 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $945,012 | 11,938 | Shares | Sole | 2025-07-22 | |
| 2025-03-31 | $2,430,790 | 27,081 | Shares | Sole | 2025-05-08 | |
| 2024-12-31 | $1,858,286 | 18,680 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $1,443,234 | 12,709 | Shares | Sole | 2024-11-05 | |
| 2024-03-31 | $286,727 | 2,173 | Shares | Sole | 2024-05-03 | |
| 2022-06-30 | $633,175 | 6,945 | Shares | Sole | 2022-08-09 | |
| 2022-03-31 | $962,036 | 11,725 | Shares | Sole | 2022-05-11 | |
| No filing history on record for this holder in this stock. | ||||||